PT1623990E - Composições e métodos para o tratamento de tumores - Google Patents
Composições e métodos para o tratamento de tumores Download PDFInfo
- Publication number
- PT1623990E PT1623990E PT05018358T PT05018358T PT1623990E PT 1623990 E PT1623990 E PT 1623990E PT 05018358 T PT05018358 T PT 05018358T PT 05018358 T PT05018358 T PT 05018358T PT 1623990 E PT1623990 E PT 1623990E
- Authority
- PT
- Portugal
- Prior art keywords
- polypeptides
- present
- treatment
- methods
- diagnosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 230000004544 DNA amplification Effects 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/005028 WO1999046281A2 (en) | 1998-03-10 | 1999-03-08 | Novel polypeptides and nucleic acids encoding the same |
US12397299P | 1999-03-11 | 1999-03-11 | |
US13345999P | 1999-05-11 | 1999-05-11 | |
PCT/US1999/012252 WO1999063088A2 (en) | 1998-06-02 | 1999-06-02 | Membrane-bound proteins and nucleic acids encoding the same |
US14065399P | 1999-06-22 | 1999-06-22 | |
US14065099P | 1999-06-22 | 1999-06-22 | |
US14475899P | 1999-07-20 | 1999-07-20 | |
US14569899P | 1999-07-26 | 1999-07-26 | |
US14622299P | 1999-07-28 | 1999-07-28 | |
US14939599P | 1999-08-17 | 1999-08-17 | |
US15168999P | 1999-08-31 | 1999-08-31 | |
PCT/US1999/020111 WO2000012708A2 (en) | 1998-09-01 | 1999-09-01 | Further pro polypeptides and sequences thereof |
PCT/US1999/021090 WO2000015796A2 (en) | 1998-09-16 | 1999-09-15 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/028313 WO2000032221A2 (en) | 1998-12-01 | 1999-11-30 | Promotion or inhibition of angiogenesis and cardiovascularization |
PCT/US1999/028301 WO2000032776A2 (en) | 1998-12-01 | 1999-12-01 | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/028634 WO2000036102A2 (en) | 1998-12-16 | 1999-12-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US2000/000219 WO2000053753A2 (en) | 1999-03-08 | 2000-01-05 | Promotion or inhibition of angiogenesis and cardiovascularization |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1623990E true PT1623990E (pt) | 2008-03-18 |
Family
ID=27578504
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05018356T PT1607402E (pt) | 1999-03-08 | 2000-02-11 | Método para o diagnóstico de tumores |
PT05018355T PT1623989E (pt) | 1999-03-08 | 2000-02-11 | ''composições e métodos para o diagnóstico de tumores'' |
PT05018358T PT1623990E (pt) | 1999-03-08 | 2000-02-11 | Composições e métodos para o tratamento de tumores |
PT05018357T PT1626058E (pt) | 1999-03-08 | 2000-02-11 | Composições e métodos para o diagnóstico de tumores |
PT05018354T PT1632499E (pt) | 1999-03-08 | 2000-02-11 | Dispositivo de detecção de impacto para automóveis. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05018356T PT1607402E (pt) | 1999-03-08 | 2000-02-11 | Método para o diagnóstico de tumores |
PT05018355T PT1623989E (pt) | 1999-03-08 | 2000-02-11 | ''composições e métodos para o diagnóstico de tumores'' |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05018357T PT1626058E (pt) | 1999-03-08 | 2000-02-11 | Composições e métodos para o diagnóstico de tumores |
PT05018354T PT1632499E (pt) | 1999-03-08 | 2000-02-11 | Dispositivo de detecção de impacto para automóveis. |
Country Status (10)
Country | Link |
---|---|
EP (7) | EP1607402B1 (pt) |
JP (6) | JP2004520003A (pt) |
KR (1) | KR100512819B1 (pt) |
AT (6) | ATE363489T1 (pt) |
AU (3) | AU2003200731C1 (pt) |
CA (5) | CA2479494C (pt) |
DK (5) | DK1607402T3 (pt) |
ES (6) | ES2321954T3 (pt) |
PT (5) | PT1607402E (pt) |
WO (1) | WO2001053486A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
EP1141285A2 (en) * | 1998-12-16 | 2001-10-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
SK10042001A3 (sk) | 1999-01-15 | 2001-12-03 | Biogen, Inc. | Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak |
US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
EP1873244A3 (en) * | 1999-06-02 | 2008-04-02 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US7589172B2 (en) | 1999-07-20 | 2009-09-15 | Genentech, Inc. | PRO256 polypeptides |
AU5951901A (en) | 2000-05-08 | 2001-11-20 | Biogen Inc | Method for promoting neovascularization |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
AU2002239505A1 (en) * | 2000-12-07 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
US20040197823A1 (en) * | 2001-09-07 | 2004-10-07 | Jamila Najib | Compositions and methods for aa4rp assay |
FR2843395A1 (fr) * | 2002-08-12 | 2004-02-13 | Genfit S A | Composition et methodes pour le dosage de l'aa4rp |
US20050123925A1 (en) * | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003227179A1 (en) * | 2002-02-08 | 2003-09-09 | Amersham Biosciences K.K. | Fused protein having glucuronyl transferase activity |
CA2462133A1 (en) | 2002-02-20 | 2003-08-28 | Kunitake Abe | Novel polypeptide |
EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
EP1494713A4 (en) | 2002-04-09 | 2005-12-28 | Biogen Idec Inc | PROCESS FOR TREATING TWEAK-RELATED CONDITIONS |
CA2491083A1 (en) * | 2002-06-28 | 2004-01-08 | Imclone Systems Incorporated | Novel polynucleotide and polypeptide sequences and uses thereof |
EP1572931B1 (en) | 2002-06-29 | 2010-08-04 | Genentech, Inc. | Methods and compositions for modulating and detecting wisp activity |
US7455834B2 (en) | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
CA2495563A1 (en) * | 2002-08-07 | 2004-02-19 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7700574B2 (en) | 2003-09-17 | 2010-04-20 | Isis Pharmaceuticals, Inc. | Modulation of RANKL expression |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
HUE029170T2 (en) | 2004-07-20 | 2017-03-28 | Genentech Inc | Preparations and methods for the use of angiopoietin-like protein 4 |
AU2005277227B2 (en) | 2004-08-19 | 2011-10-06 | Biogen Ma Inc. | Refolding transforming growth factor beta family proteins |
US20090124993A1 (en) | 2005-02-17 | 2009-05-14 | Burkly Linda C | Treating neurological disorders |
BRPI0608012A2 (pt) * | 2005-03-07 | 2009-11-03 | Genentech Inc | método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
JP5583005B2 (ja) | 2007-05-01 | 2014-09-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管新生を増大させるための組成物および方法 |
AU2008269689A1 (en) * | 2007-06-27 | 2008-12-31 | Auckland Uniservices Limited | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
WO2011027132A1 (en) * | 2009-09-03 | 2011-03-10 | Cancer Research Technology Limited | Clec14a inhibitors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
EP0654092B1 (en) * | 1992-06-26 | 2003-09-10 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using p90 and p53 antibodies or probes |
CA2153480A1 (en) * | 1993-11-12 | 1995-06-01 | Kenichi Matsubara | Gene signature |
CA2296287A1 (en) * | 1997-08-01 | 1999-02-11 | Genset | 5' ests for secreted proteins expressed in prostate |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
US7122373B1 (en) * | 1998-05-14 | 2006-10-17 | Nuvelo, Inc. | Human genes and gene expression products V |
JP2002501738A (ja) * | 1998-01-30 | 2002-01-22 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 67個のヒト分泌タンパク質 |
JP2002516067A (ja) * | 1998-03-02 | 2002-06-04 | ミレニアム・フアーマシユーチカルズ・インコーポレーテツド | 新規fdrgタンパク質および核酸分子、ならびにそのための用途 |
DE19818620A1 (de) * | 1998-04-21 | 1999-10-28 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Blase-Normal |
JP2002518010A (ja) * | 1998-06-16 | 2002-06-25 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 94個のヒト分泌タンパク質 |
AU4643699A (en) * | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
WO2000004135A2 (en) * | 1998-07-16 | 2000-01-27 | Incyte Pharmaceuticals, Inc. | Human scad-related molecules, scrm-1 and scrm-2 |
WO2000006728A2 (en) * | 1998-07-28 | 2000-02-10 | Incyte Pharmaceuticals, Inc. | Phosphorylation effectors |
JP2002537757A (ja) * | 1998-08-24 | 2002-11-12 | アルファジーン・インコーポレイテッド | 分泌タンパク質及びそれらをコードするポリヌクレオチド |
WO2001053455A2 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
JP2003518913A (ja) * | 1998-12-11 | 2003-06-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ニューロン関連タンパク質 |
JP2004507202A (ja) * | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」 |
ES2287020T3 (es) * | 1999-06-02 | 2007-12-16 | Genentech, Inc. | Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas. |
AU1916101A (en) * | 1999-11-12 | 2001-06-06 | Human Genome Sciences, Inc. | 19 human secreted proteins |
WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
-
2000
- 2000-02-11 WO PCT/US2000/003565 patent/WO2001053486A1/en not_active Application Discontinuation
- 2000-02-11 PT PT05018356T patent/PT1607402E/pt unknown
- 2000-02-11 DK DK05018356T patent/DK1607402T3/da active
- 2000-02-11 EP EP05018356A patent/EP1607402B1/en not_active Expired - Lifetime
- 2000-02-11 EP EP05018358A patent/EP1623990B1/en not_active Expired - Lifetime
- 2000-02-11 AT AT05018354T patent/ATE363489T1/de not_active IP Right Cessation
- 2000-02-11 EP EP05018357A patent/EP1626058B1/en not_active Expired - Lifetime
- 2000-02-11 ES ES05018353T patent/ES2321954T3/es not_active Expired - Lifetime
- 2000-02-11 EP EP05018354A patent/EP1632499B9/en not_active Expired - Lifetime
- 2000-02-11 ES ES05018358T patent/ES2298896T3/es not_active Expired - Lifetime
- 2000-02-11 PT PT05018355T patent/PT1623989E/pt unknown
- 2000-02-11 DK DK05018355T patent/DK1623989T3/da active
- 2000-02-11 AT AT05018357T patent/ATE377025T1/de not_active IP Right Cessation
- 2000-02-11 CA CA002479494A patent/CA2479494C/en not_active Expired - Fee Related
- 2000-02-11 PT PT05018358T patent/PT1623990E/pt unknown
- 2000-02-11 PT PT05018357T patent/PT1626058E/pt unknown
- 2000-02-11 CA CA002479511A patent/CA2479511A1/en not_active Abandoned
- 2000-02-11 ES ES05018354T patent/ES2290834T3/es not_active Expired - Lifetime
- 2000-02-11 ES ES05018356T patent/ES2279473T3/es not_active Expired - Lifetime
- 2000-02-11 AT AT05018353T patent/ATE422536T1/de not_active IP Right Cessation
- 2000-02-11 AT AT05018356T patent/ATE348108T1/de not_active IP Right Cessation
- 2000-02-11 EP EP00907270A patent/EP1173563A1/en not_active Withdrawn
- 2000-02-11 CA CA002365610A patent/CA2365610A1/en not_active Abandoned
- 2000-02-11 EP EP05018353A patent/EP1626084B1/en not_active Expired - Lifetime
- 2000-02-11 AT AT05018358T patent/ATE380195T1/de not_active IP Right Cessation
- 2000-02-11 CA CA002479498A patent/CA2479498A1/en not_active Abandoned
- 2000-02-11 KR KR10-2001-7011391A patent/KR100512819B1/ko not_active IP Right Cessation
- 2000-02-11 JP JP2001553947A patent/JP2004520003A/ja active Pending
- 2000-02-11 CA CA002479476A patent/CA2479476C/en not_active Expired - Fee Related
- 2000-02-11 ES ES05018357T patent/ES2296029T3/es not_active Expired - Lifetime
- 2000-02-11 EP EP05018355A patent/EP1623989B1/en not_active Expired - Lifetime
- 2000-02-11 DK DK05018357T patent/DK1626058T3/da active
- 2000-02-11 PT PT05018354T patent/PT1632499E/pt unknown
- 2000-02-11 AT AT05018355T patent/ATE364628T1/de not_active IP Right Cessation
- 2000-02-11 ES ES05018355T patent/ES2289630T3/es not_active Expired - Lifetime
- 2000-02-11 DK DK05018358T patent/DK1623990T3/da active
- 2000-02-11 DK DK05018354T patent/DK1632499T3/da active
-
2002
- 2002-12-26 JP JP2002378692A patent/JP2004201653A/ja active Pending
- 2002-12-26 JP JP2002378517A patent/JP2004201652A/ja active Pending
- 2002-12-27 JP JP2002379711A patent/JP2004201654A/ja active Pending
- 2002-12-27 JP JP2002380537A patent/JP2004229504A/ja active Pending
- 2002-12-27 JP JP2002379406A patent/JP2004229503A/ja active Pending
-
2003
- 2003-02-25 AU AU2003200731A patent/AU2003200731C1/en not_active Ceased
- 2003-02-25 AU AU2003200722A patent/AU2003200722B2/en not_active Ceased
- 2003-02-26 AU AU2003200740A patent/AU2003200740C1/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1623990E (pt) | Composições e métodos para o tratamento de tumores | |
WO2000053755A3 (en) | Compositions and methods for the treatment of tumor | |
IL193366A0 (en) | Fibroblast growth factor -19 | |
AU4851900A (en) | Compositions and methods for the treatment of tumor | |
KR100473551B1 (en) | Compositions and Methods for The Treatment of Tumor | |
WO1999035170A8 (en) | Compositions and methods for the treatment of tumor | |
WO1999014327A3 (en) | Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer | |
WO2003032813A3 (en) | Methods for the treatment of carcinoma | |
WO2001009189A3 (en) | Compositions and methods for the treatment of tumors | |
WO2000037640A3 (en) | Compositions and methods for the treatment of tumor | |
WO2004075835A3 (en) | Methods for the treatment of renal cell carcinoma | |
WO2000015666A3 (en) | Compositions and methods for the treatment of tumors |